Preview

Атеротромбоз

Расширенный поиск

СТРАТЕГИЯ МИНИМИЗАЦИИ РИСКОВ КРОВОТЕЧЕНИЙ У БОЛЬНЫХ С МЕРЦАТЕЛЬНОЙ АРИТМИЕЙ, ПОЛУЧАЮЩИХ КОМБИНИРОВАННУЮ АНТИТРОМБОТИЧЕСКУЮ ТЕРАПИЮ ПОСЛЕ ЧРЕСКОЖНОГО КОРОНАРНОГО ВМЕШАТЕЛЬСТВА

https://doi.org/10.21518/2307-1109-2018-1-33-42

Полный текст:

Аннотация

Применение комбинированной антитромботической у пациентов с мерцательной аритмией, перенесших чрескожные коронарные вмешательства, ассоциировано с повышенным риском кровотечений. В связи с этим одним из стратегических приоритетов в ведении данной клинической группы является минимизация геморрагического риска. Статья посвящена обсуждению стратегии снижения риска кровотечений в данной категории пациентов. Особое внимание уделяется месту прямых пероральных антикоагулянтов в реализации данной стратегии.

Об авторе

Д. А. Затейщиков
Городская клиническая больница № 51 ДЗ; Центральная государственная медицинская академия УД Президента РФ
Россия
Москва


Список литературы

1. Valgimigli M et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2018, 39 (3): 213–260.

2. Costa F et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individualpatient datasets from clinical trials. The Lancet, 2017, 389 (10073): 1025–1034.

3. Thygesen K et al. Third universal definition of myocardial infarction. Circulation, 2012, 126 (16): 2020–35.

4. Mehran R et al. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. JACC Cardiovasc Interv, 2011, 4 (6): 654–664.

5. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med, 1998, 338 (21): 1498–505.

6. Cannon CP et al. Oral glycoprotein IIb / IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation, 2000, 102 (2): 149–156.

7. Mahaffey KW et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation, 2011, 124 (5): 544–554.

8. Singh M. Bleeding Avoidance Strategies During Percutaneous Coronary Interventions. Journal of the American College of Cardiology, 2015, 65 (20): 2225–2238.

9. Subherwal S et al. Baseline Risk of Major Bleeding in Non – ST-Segment – Elevation Myocardial Infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC / AHA guidelines) Bleeding Score. Circulation, 2009, 119 (14): 1873–1882.

10. Mathews R et al. In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry (R) – GWTG. Am J Cardiol, 2011, 107 (8): 1136–1143.

11. O’Brien EC et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. European Heart Journal, 2015, 36 (46): 3258–3264.

12. Hijazi Z et al. The novel biomarker-based ABC (age, biomarkers, clinical history) – bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet, 2016, 387 (10035): 2302–2311.

13. Dewilde WJM et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. The Lancet, 2013, 381 (9872): 1107–1115.

14. Gibson CM et al. Prevention of Bleeding in Patient s with Atrial Fibrillation Undergoing PCI. New England Journal of Medicine, 2016, 375 (25): 2423–2434.

15. Cannon CP et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med, 2017, 377 (16): 1513–1524.

16. Steffel J et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist or al anticoagulants in patients with atrial fibrillation. Eur Heart J, 2018: ehy136-ehy136.

17. Eikelboom JW et al. Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. British Journal of Anaesthesia, 2018, 120 (4): 645–656.

18. Pollack CV Jr et al. Idarucizumab for Dabigatr an Reversal – Full Cohort Analysis. N Engl J Med, 2017, 377 (5): 431–441.


Для цитирования:


Затейщиков Д.А. СТРАТЕГИЯ МИНИМИЗАЦИИ РИСКОВ КРОВОТЕЧЕНИЙ У БОЛЬНЫХ С МЕРЦАТЕЛЬНОЙ АРИТМИЕЙ, ПОЛУЧАЮЩИХ КОМБИНИРОВАННУЮ АНТИТРОМБОТИЧЕСКУЮ ТЕРАПИЮ ПОСЛЕ ЧРЕСКОЖНОГО КОРОНАРНОГО ВМЕШАТЕЛЬСТВА. Атеротромбоз. 2018;(1):33-42. https://doi.org/10.21518/2307-1109-2018-1-33-42

For citation:


Zateishchikov D.A. STRATEGY TO MINIMIZE THE BLEEDING RISKS IN PATIENTS WITH ATRIAL FIBRILLATION WHO RECEIVE COMBINED ANTITHROMBOTIC THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION. Atherothrombosis Journal. 2018;(1):33-42. (In Russ.) https://doi.org/10.21518/2307-1109-2018-1-33-42

Просмотров: 132


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)